Marc Hirsch, MD
Ophthalmology · Milwaukee, WINPI 1386624120
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.8% of the total across 85 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 20.0% — the pattern of someone who eats at a lot of different presentations.
Across 85 payments — averaging $39.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron Healthcare Solutions, Inc.$673
- Alcon$607
- Glaukos Corporation$455
- Apellis Pharmaceuticals, Inc.$317
- NEW World Medical,inc.$271
- Tarsus Pharmaceuticals, Inc.$185
- plus $850 from 18 others
What the payments were for
- Food & beverage$3,31899%
- Education$411%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 14 | $673 |
| Alcon | 8 | $607 |
| Glaukos Corporation | 5 | $455 |
| Apellis Pharmaceuticals, Inc. | 6 | $317 |
| NEW World Medical,inc. | 12 | $271 |
| Tarsus Pharmaceuticals, Inc. | 4 | $185 |
| AbbVie(2 entities) | 3 | $121 |
| The Cameron-ehlen Group, Inc. | 2 | $110 |
| Ocular Therapeutix, Inc. | 3 | $88 |
| Harrow Eye, LLC | 3 | $75 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 4 | $63 |
| Dompe US, Inc. | 3 | $59 |
| Omeros Corporation | 3 | $51 |
| Rayner Intraocular Lenses Limited | 2 | $50 |
| Sandoz | 1 | $38 |
| Thea Pharma Inc. | 2 | $33 |
| Astellas Pharma US Inc | 1 | $31 |
| Biotissue Holdings Inc. | 3 | $23 |
| Novartis | 1 | $20 |
| Pacira Pharmaceuticals Incorporated | 1 | $20 |
| Rxsight Inc | 1 | $20 |
| Bausch & Lomb Americas Inc. | 1 | $17 |
| Sight Sciences, Inc. | 1 | $16 |
| Quidel Corporation | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EYLEA HD$467
- Syfovre$249
- CE-marked KXLA system$176
- Luxor$143
- Clareon$122
- XDEMVY$115
- KXL System$107
- Photrexa Viscous and Photrexa$107
How this compares
$3,359 in reported general payments places this provider in the 85th percentile of 337 ophthalmology providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 129 | $105,565 |
| LumiganBimatoprost | 77 | $34,761 |
| XiidraLifitegrast | 16 | $19,829 |
| Cyclosporine | 17 | $10,329 |
| CombiganBrimonidine Tartrate/Timolol | 19 | $7,946 |
| Prednisolone Acetate | 180 | $6,822 |
| IlevroNepafenac | 17 | $6,528 |
| Fluorometholone | 49 | $4,204 |
| Latanoprost | 404 | $3,461 |
| MoxifloxacinMoxifloxacin Hcl | 113 | $3,234 |
| Ketorolac Tromethamine | 97 | $2,239 |
| Bromfenac Sodium | 11 | $1,928 |
| Brimonidine Tartrate | 32 | $1,560 |
| Bimatoprost | 12 | $1,370 |
| Difluprednate | 14 | $1,237 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan | $121 | $148,273225 claims |
| Bausch & Lomb Americas Inc.Xiidra | $17 | $19,82916 claims |
| NovartisIlevro | $20 | $6,52817 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 337 ophthalmology providers in Wisconsin.
Other ophthalmology in Milwaukee
- Dennis HanMilwaukee$8K
- Charles YangMilwaukee$6K
- Michael RacitiMilwaukee$6K
- Monica Gonzalez-CollazoMilwaukee$5K
- Sarah CarballoMilwaukee$4K
- Smith Ann ChisholmMilwaukee$3K
- Nicholas FrameMilwaukee$3K
- Charles McCannaMilwaukee$2K
- Jacquelyn LaplantMilwaukee$2K
- Robert BjerregaardMilwaukee$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.